NCT06119425 is a NA clinical trial of blood-based CRC screening in Cancer Colon, sponsored by Ballad Health.

Who is sponsoring NCT06119425?

NCT06119425 is sponsored by Ballad Health.

What drugs are being tested in NCT06119425?

Interventions in NCT06119425: blood-based CRC screening.

What condition does NCT06119425 study?

NCT06119425 studies Cancer Colon.

Is NCT06119425 still recruiting?

NCT06119425 is currently completed. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT06119425

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice Highlands

Completed NA Last updated 10 February 2026

What this trial tests

NA trial testing blood-based CRC screening in Cancer Colon in 231 participants. Completed in 30 April 2025.

Timeline

12 October 2023

Primary endpoint
30 April 2025

30 April 2025

Quick facts

Lead sponsor	Ballad Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	231
Start date	12 October 2023
Primary completion	30 April 2025
Estimated completion	30 April 2025
Sites	1 location across United States

Drugs / interventions tested

blood-based CRC screening

Conditions studied

Cancer Colon — all drugs for Cancer Colon →

Sponsor

Ballad Health

Who can join

Adults 45 to 84, any sex, with Cancer Colon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective implementation study that will include patients that are identified as being average risk for colorectal cancer (CRC) according to USPSTF guidelines and who have opted to be screened for CRC. The purpose of this study is to understand implementation of a noninvasive screening test in primary care and internal medicine clinical settings, and the impact on patient acceptability and adherence of CRC screening.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Progress in Clinical Research in Secondary Prevention and Early Detection of Colorectal Cancer.
Partyka O, Pajewska M, Czerw A, Deptała A, et al · · 2025 · cited 2× · PMID 39941735 · DOI 10.3390/cancers17030367

Verify or expand the search:

Other Ballad Health trials

Trials by the same sponsor.

NCT06849518 — Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06119425 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ballad Health
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06119425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing